Among them, bosutinib (SKI-606) could reduce the growth and motility of CRC cells by preventing pp60(c-Src)-dependent β-catenin tyrosine phosphorylation and its nuclear signaling, and may be a promising choice for the treating CRC42. Here, SRC is linked to colorectal carcinoma.